Janssen Inc. v. Apotex Inc., 2022 FC 996
| Jurisdiction | Federal Jurisdiction (Canada) |
| Court | Federal Court (Canada) |
| Citation | 2022 FC 996 |
| Date | 06 July 2022 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
4 practice notes
-
2022 Year In Review: IP Litigation
...a generic drug manufacturer is said to induce prescribing physicians (Janssen Inc v Apotex Inc, 2022 FC 107; Janssen Inc v Apotex Inc, 2022 FC 996; and Janssen Inc v Pharmascience, 2022 FC 62). Similarly, in UPL NA Inc v AgraCity Crop & Nutrition Ltd, 2022 FC 1422, an action for patent infr......
-
Apotex Inc. v. Janssen Inc., 2023 FCA 220
...In an action pursuant to the Patented Medicines (Notice of Compliance) Regulations, S.O.R./93-133 (the Regulations), the Federal Court (2022 FC 996, per Justice Christine M. Pallotta) agreed with the respondents’ allegation and enjoined Apotex from various activities involving Apo-Ma......
-
Canadian Patent Law: 2022 Year In Review
...the claimed subject matter was not obvious to try and Pharmascience's obviousness defence failed. The decision of Janssen v Apotex, ( 2022 FC 996) related to infringement via inducement. The patent at issue claimed, generally speaking, the use of the active ingredient macitentan in combinat......
-
Janssen Succeeds On Infringement Against Apotex In Macitentan Combination Patent Case
...Apotex would infringe Janssen's patent relating to Janssen's OPSUMIT (macitentan) by selling APO-MACITENTAN: Janssen Inc v Apotex Inc, 2022 FC 996. Apotex did not challenge Canadian Patent No. 2,659,770 (770 Patent) was the subject of an earlier s. 6(1) action involving Janssen and Sandoz, ......
1 cases
-
Apotex Inc. v. Janssen Inc., 2023 FCA 220
...In an action pursuant to the Patented Medicines (Notice of Compliance) Regulations, S.O.R./93-133 (the Regulations), the Federal Court (2022 FC 996, per Justice Christine M. Pallotta) agreed with the respondents’ allegation and enjoined Apotex from various activities involving Apo-Ma......
3 firm's commentaries
-
2022 Year In Review: IP Litigation
...a generic drug manufacturer is said to induce prescribing physicians (Janssen Inc v Apotex Inc, 2022 FC 107; Janssen Inc v Apotex Inc, 2022 FC 996; and Janssen Inc v Pharmascience, 2022 FC 62). Similarly, in UPL NA Inc v AgraCity Crop & Nutrition Ltd, 2022 FC 1422, an action for patent infr......
-
Canadian Patent Law: 2022 Year In Review
...the claimed subject matter was not obvious to try and Pharmascience's obviousness defence failed. The decision of Janssen v Apotex, ( 2022 FC 996) related to infringement via inducement. The patent at issue claimed, generally speaking, the use of the active ingredient macitentan in combinat......
-
Janssen Succeeds On Infringement Against Apotex In Macitentan Combination Patent Case
...Apotex would infringe Janssen's patent relating to Janssen's OPSUMIT (macitentan) by selling APO-MACITENTAN: Janssen Inc v Apotex Inc, 2022 FC 996. Apotex did not challenge Canadian Patent No. 2,659,770 (770 Patent) was the subject of an earlier s. 6(1) action involving Janssen and Sandoz, ......